Q2 2025 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2025-08-14 · accession 0001420506-25-002188
$520.2M
Reported value
17
Positions
2025-06-30
Period end
The Brief · Caligan Partners LP · Q2 2025
AI · grounded in 13F
Caligan Partners LP established a new position in VRNA worth $135.9M. The fund also initiated stakes in LQDA for $101.2M and EXEL for $67.2M. Other new additions include AGIO, 2GH, and EOLS. The fund ended the period with 17 positions and total AUM of $520.2M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 925050106 | VRNA | VERONA PHARMA PLC | $135.9M | 26.1% | 1,436,878 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $101.2M | 19.4% | 8,118,892 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $67.2M | 12.9% | 1,525,730 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $35.6M | 6.85% | 1,071,258 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $34.6M | 6.64% | 656,999 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $30.8M | 5.92% | 3,341,970 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $27.3M | 5.25% | 2,017,352 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $23.4M | 4.50% | 636,835 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $15.2M | 2.92% | 1,435,130 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $12.8M | 2.46% | 1,674,400 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $10.6M | 2.03% | 2,342,609 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $6.9M | 1.32% | 1,543,014 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $5.7M | 1.10% | 638,908 | Common | SOLE |
| 81642T209 | SLS | SELLAS LIFE SCIENCES GROUP I | $5.0M | 0.97% | 2,300,000 | CALL | SOLE |
| 92511W108 | VRCA | VERRICA PHARMACEUTICALS INC | $4.9M | 0.94% | 9,239,119 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $1.8M | 0.35% | 189,950 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $1.3M | 0.24% | 200,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.